RxDoctor Payments Data

Samuel Groves, MD

Interventional Cardiology · Charleston, WVNPI 1821035304

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 56.4% of the total. That places this record below the midpoint for interventional cardiology clinicians in WV, where the typical reported total is $7,222.

$2,906in general payments, 2019–2025

Across 164 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Boston Scientific$380
  • Kestra Medical Technology Services, Inc.$220
  • Cardinal Health 200 LLC$217
  • Abiomed$81
  • Shockwave Medical, Inc$69
  • plus $299 from 9 others

What the payments were for

  • Food & beverage$2,906100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,906 in reported general payments places this provider in the 30th percentile of 46 interventional cardiology providers in West Virginia.

See all interventional cardiology providers in West Virginia

Medicare billing

Part B allowed, 2024
$124,490
Medicare patients
1,184
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$152,560
EntrestoSacubitril/Valsartan63$67,324
XareltoRivaroxaban40$44,049
JardianceEmpagliflozin11$11,520
Metoprolol Succinate158$1,782
Isosorbide Mononitrate ErIsosorbide Mononitrate40$1,157
ClopidogrelClopidogrel Bisulfate95$1,069
Atorvastatin Calcium68$645
Rosuvastatin Calcium41$609
Potassium Chloride17$437
Carvedilol63$408
Torsemide20$404
Nitroglycerin25$308
Pravastatin Sodium15$254
Spironolactone37$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$152,560147 claims
Johnson & JohnsonXarelto$18$44,04940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 46 interventional cardiology providers in West Virginia.

Other interventional cardiology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →